Abstract
Currently, the effect of miR-130 on non-small cell lung cancer (NSCLC) remains controversial. In this study, the expression of miR-130 and lncRNA MRPL39 in tumor and non-tumor tissues of NSCLC patients was examined using real-time PCR (RT-PCR) and correlated with the prognosis of NSCLC. The phenotypic effects of miR-130 and MRPL39 on proliferation and migration of NSCLC cell line A549 cells were assessed through CCK-8 and Transwell assays with miR-130 mimic and MRPL39 (mitochondrial ribosomal protein L39) overexpressed plasmid transfection. StarBase/TargetScan analysis and dual-luciferase reporter gene assays were conducted to investigate the relationship between MRPL39, miR-130, and Tuberculosis sclerosis 1 (TSC1). MiR-130 was overexpressed, and MRPL39 was downregulated in NSCLC tissues and cells. Inhibition of miR-130 expression and overexpression of MRPL39 resulted in the inhibition of the viability and migration of A549 cells. MRPL39 is a potential upstream regulatory long non-coding RNA of miR-130, and its expression is negatively regulated by miR-130. TSC1 was identified as a target of miR-130, suppressing the antitumor effects of FGD5-AS1 silencing on GBM cells. After overexpression of MRPL39, the mRNA and protein levels of TSC1 in A549 cells significantly increased. However, after transfection with miR-130 mimic, the up-regulation of mRNA and protein was inhibited, leading to the suppression of cell proliferation and migration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beltran AS, Blancafort P (2011) Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 6:224–235. https://doi.org/10.4161/epi.6.2.13700
Bridges MC, Daulagala AC, Kourtidis A (2021) LNCcation: lncRNA localization and function. J Cell Biol 220:e202009045
Cao HL, Liu ZJ, Huang PL et al (2019) lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci 23:1012–1021. https://doi.org/10.26355/eurrev_201902_16988
Cech TR, Steitz JA (2014) The noncoding RNA revolution—trashing old rules to forge new ones. Cell 157:77–94
Chaft JE, Rimner A, Weder W et al (2021) Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol 18:547–557
Chen Z, Chen Z, Xu S, Zhang Q (2021) LncRNA SOX2-OT/miR-30d-5p/PDK1 regulates PD-L1 checkpoint through the mTOR signaling pathway to promote non-small cell lung cancer progression and immune escape. Front Genet 12:674856. https://doi.org/10.3389/fgene.2021.674856
de la Carolina P, Nuria B (2020) Radiomics in lung cancer for oncologists. J Clin Transl Res. 6(4):1247–2134. https://doi.org/10.18053/jctres.06.2020s4.002
Dezfuli NK, Adcock IM, Alipoor SD et al (2022) The miR-196a SNP Rs11614913 but not the miR-499 rs37464444 SNP is a risk factor for non-small cell lung cancer in an Iranian population. Tanaffos 21:15–23
Duan J, Zhang H, Qu Y et al (2016) Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget 7:44522–44533. https://doi.org/10.18632/oncotarget.9936
Dykes IM, Emanueli C (2017) Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinform 15:177–186
Egawa H, Jingushi K, Hirono T et al (2016) The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep 6:20574. https://doi.org/10.1038/srep20574
Fuchs A, König K, Heukamp LC et al (2014) Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer. Diagn Pathol. https://doi.org/10.1186/1746-1596-9-48
Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179–190
Jin M, Liu X, Wu Y et al (2022a) Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness. Cancer Cell Int 22:219. https://doi.org/10.1186/s12935-022-02618-7
Jin Y-C, Wu M-Q, Chen K-Z, Wang J (2022b) Role of circulating tumor DNA in the management of patients with non-small cell lung cancer. Glob Transl Med 1:96. https://doi.org/10.36922/gtm.v1i1.96
Kotulska K, Larysz-bRYSZ M, Grajkowska W et al (2009) Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. Pediatr Dev Pathol 12:89–95. https://doi.org/10.2350/06-11-0191.1
Kuru Cİ, Akgöl S (2022) Advanced fabrication of miRNA-based electrochemical nanobiosensor for diagnosis of breast cancer. Nanomanufacturing 2:146–175. https://doi.org/10.3390/nanomanufacturing2030011
Lai M, Zou W, Han Z et al (2021) TSC1 regulates tight junction independent of mTORC1. Proc Natl Acad Sci USA 118:e2020891118. https://doi.org/10.1073/pnas.2020891118
Li C, Chen Y, Chen X et al (2017) Downregulation of microRNA-193b-3p promotes autophagy and cell survival by targeting TSC1/mTOR signaling in NSC-34 cells. Front Mol Neurosci 10:160. https://doi.org/10.3389/fnmol.2017.00160
Li H, Xu C, Lu X (2023) A case report of refractory pulmonary adenocarcinoma. Adv Radiotherapy Nuclear Med 1:0883. https://doi.org/10.36922/arnm.0883
Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. RNA Biol 10:924–933
Mallela K, Kumar A (2021) Role of TSC1 in physiology and diseases. Mol Cell Biochem 476:2269–2282
Pfirmann P, Combe C, Rigothier C (2021) Tuberous sclerosis complex: a review. Rev Med Int 42:108–114
Qi L, Liu F, Zhang F et al (2018) lncRNA NEAT1 competes against let-7a to contribute to non-small cell lung cancer proliferation and metastasis. Biomed Pharmacother 103:1507–1515. https://doi.org/10.1016/j.biopha.2018.04.053
Qu J, Jiang M, Wang L et al (2020) Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomed Pharmacother 127:109996
Rennie W, Kanoria S, Liu C et al (2016) STarMirDB: a database of microRNA binding sites. RNA Biol 13:554–560. https://doi.org/10.1080/15476286.2016.1182279
Rodriguez de Dios N, Murcis-Meijia M, David S (2020) Current and future strategies in radiotherapy for small-cell lung cancer. J Clin Transl Res 6(4):97–108. https://doi.org/10.18053/jctres.06.2020s4.005
Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203–222
Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomark Prev 28:1563–1579. https://doi.org/10.1158/1055-9965.EPI-19-0221
Tsuboi M, Ohira T, Saji H et al (2007) The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 13:73–77
Wang M, Wang W, Wang J, Zhang J (2018) MiR-182 promotes glucose metabolism by upregulating hypoxia-inducible factor 1α in NSCLC cells. Biochem Biophys Res Commun 504:400–405. https://doi.org/10.1016/j.bbrc.2018.06.035
Wang X, Xu Y, Zhang S et al (2022) MicroRNA-195 rescues the impaired MS-dCA1 neural circuit and spatial memory in rats with chronic cerebral hypoperfusion. Adv Neurol 1:116. https://doi.org/10.36922/an.v1i2.116
Xu W, Wu Q, Huang A (2022) Emerging role of LncRNAs in autoimmune lupus. Inflammation 45:937–948
Ye L, Wang Y, Nie L et al (2017) MiR-130 exerts tumor suppressive function on the tumorigenesis of human non-small cell lung cancer by targeting PTEN. Am J Transl Res 9:1856–1865
Yu MJ, Zhao N, Shen H, Wang H (2018) Long noncoding RNA MRPL39 inhibits gastric cancer proliferation and progression by directly targeting miR-130. Genet Test Mol Biomark 22:1856–1865. https://doi.org/10.1089/gtmb.2018.0151
Zeng S, Lin C, Huang Y (2023) miR-375 combined with SHOX2 methylation has higher diagnostic efficacy for non-small-cell lung cancer. Mol Biotechnol 65:1187–1197. https://doi.org/10.1007/s12033-022-00604-y
Zhang Q, Zhang B, Sun L et al (2018) MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway. Cell Biochem Funct 36:194–202. https://doi.org/10.1002/cbf.3331
Zhao W, Geng D, Li S et al (2018) LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med 7:842–855. https://doi.org/10.1002/cam4.1353
Zhi ZFAZ (2019) Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2019 edition). Chin J Lung Cancer 22:1063–1077. https://doi.org/10.3779/j.issn.1009-3419.2019.07.01
Zhu K, Zhu J, Geng J et al (2021) circSNX6 (hsa_circ_0031608) enhances drug resistance of non-small cell lung cancer (NSCLC) via miR-137. Biochem Biophys Res Commun 567:79–85. https://doi.org/10.1016/j.bbrc.2021.06.032
Funding
The second batch of major (key) science and technology research projects in Jinhua City in 2021, 2021-3-113.
Author information
Authors and Affiliations
Contributions
The authors are contributed to the preparation of the manuscript and discussion. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Ethical approval
This study was conducted with the informed consent of NSCLC patients and approved by the Ethics Committee of Jinhua People’s Hospital (Approved No. IRB-2021037-R).
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fan, Q., Bao, X., Zhao, H. et al. LncRNA MRPL39 inhibits cell proliferation and migration by regulating miR-130/TSC1 axis in non-small cell lung cancer. 3 Biotech 14, 125 (2024). https://doi.org/10.1007/s13205-024-03975-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-024-03975-y